9MW1911

DRUG2 trials

Sponsors

Mabwell (Shanghai) Bioscience Co., Ltd.

Conditions

Chronic Obstructive Pulmonary Disease COPDModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase 1

Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Active, not recruitingNCT06175351

Mabwell (Shanghai) Bioscience Co., Ltd.Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Start: 2023-07-06End: 2025-09-30Target: 80Updated: 2025-05-20

Phase 2

A Study to Evaluate 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

RecruitingNCT07292714

Mabwell (Shanghai) Bioscience Co., Ltd.Chronic Obstructive Pulmonary Disease COPD

Start: 2025-07-15End: 2028-02-29Target: 360Updated: 2025-12-18